Natera (NASDAQ:NTRA) Price Target Raised to $157.00

Natera (NASDAQ:NTRA) had its target price raised by Craig Hallum from $121.00 to $157.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

A number of other analysts have also recently weighed in on NTRA. Robert W. Baird raised their target price on shares of Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday. Morgan Stanley raised their price objective on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. Canaccord Genuity Group boosted their target price on Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, Piper Sandler reissued an “overweight” rating and issued a $150.00 price target on shares of Natera in a research note on Friday, September 13th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $137.65.

Natera Stock Down 3.3 %

Shares of NTRA stock opened at $146.06 on Wednesday. Natera has a 1 year low of $52.01 and a 1 year high of $167.79. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.01 and a current ratio of 4.39. The business’s fifty day moving average is $127.38 and its 200-day moving average is $115.46. The stock has a market cap of $19.28 billion, a PE ratio of -82.99 and a beta of 1.53.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same period in the previous year, the company earned ($0.95) earnings per share. Natera’s revenue was up 63.9% compared to the same quarter last year. Equities analysts expect that Natera will post -1.96 earnings per share for the current fiscal year.

Insider Activity

In other Natera news, Director Rowan E. Chapman sold 2,614 shares of Natera stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $127.68, for a total value of $333,755.52. Following the completion of the sale, the director now directly owns 7,969 shares in the company, valued at $1,017,481.92. The trade was a 24.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 4,728 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $146.41, for a total transaction of $692,226.48. Following the completion of the sale, the chief executive officer now directly owns 185,034 shares of the company’s stock, valued at $27,090,827.94. This represents a 2.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 36,821 shares of company stock worth $4,776,878 in the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Natera

Large investors have recently bought and sold shares of the business. Wellington Management Group LLP boosted its position in Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after purchasing an additional 1,883,481 shares during the period. Farallon Capital Management LLC boosted its holdings in shares of Natera by 13.6% during the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after buying an additional 532,874 shares during the period. First Light Asset Management LLC grew its stake in Natera by 295.9% in the 1st quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock valued at $60,063,000 after buying an additional 490,822 shares during the last quarter. AQR Capital Management LLC grew its stake in Natera by 257.6% in the 2nd quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock valued at $70,553,000 after buying an additional 469,327 shares during the last quarter. Finally, PointState Capital LP raised its holdings in Natera by 112.0% in the 3rd quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock worth $99,343,000 after acquiring an additional 413,468 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.